Pathological examination of the affected human tissue is key to understanding the possible mechanisms operating in the disease. In multiple sclerosis (MS), studies of central nervous system (CNS) tissues reveal the inflammatory nature of the disease associated with demyelination and
axonal damage. Based on the concept of a pathogenic adaptive immune response, immunosuppressive therapies have been developed in an attempt to block or inhibit the potentially pathogenic T and B cells. More recently, re-examination of the neuropathology has led to a resurgence of interest
in the neurodegenerative aspects of the disease, the involvement of cortical damage as well as the role of innate immunity in MS. These ideas have led to paradigm shifts from MS being the result of autoimmunity to myelin due to initial adaptive immune responses, to that of a neurodegenerative
disease in which, besides T and B cells, innate immunity may play a major role in the disease process. The neuropathological studies have undoubtedly influenced pharmaceutical interest in development of neuroprotective approaches. Here we review the latest findings from pathological studies
of MS tissues and discuss the relevance of these findings for future therapeutic approaches.
No Supplementary Data
No Article Media
Central nervous system;
Myelin oligodendrocyte glycoprotein;
luxol fast blue;
Document Type: Research Article
Publication date: 01 August 2012
More about this publication?
CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites